An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno Associated Virus Vector for Gene Therapy of Adults And Children With Retinal Dystrophy Associated With Defects in RPE65 (LCA)

Trial Profile

An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno Associated Virus Vector for Gene Therapy of Adults And Children With Retinal Dystrophy Associated With Defects in RPE65 (LCA)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs A001-MeiraGTx (Primary)
  • Indications Retinal dystrophies
  • Focus Adverse reactions
  • Acronyms OPTIRPE65
  • Most Recent Events

    • 16 Aug 2017 Planned End Date changed from 29 Apr 2017 to 1 Oct 2018.
    • 16 Aug 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Oct 2018.
    • 08 Feb 2017 According to a MeiraGTx media release, the company has successfully completed dosing of patients in the second cohort in its clinical trial for Leber's Congenital Amaurosis with RPE65 mutations
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top